From Medscape Neurology

Coverage from the

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2024

October 15 - 18, 2024; Savannah, Georgia

October 15 - 18, 2024 Savannah, Georgia

Conference News

AANEM 2024 New Drug Options Abound for Duchenne Muscular Dystrophy
Medscape Medical News, November 4, 2024
AANEM 2024 Myasthenia Gravis: Where Does Traditional Therapy Fit in?
Medscape Medical News, November 4, 2024
AANEM 2024 Digital Tool May Help Neurologists Assess Steroid Toxicity
Medscape Medical News, October 25, 2024
AANEM 2024 Veterans Affairs Hailed as a ‘Bright Spot’ in ALS Care
Medscape Medical News, October 25, 2024
AANEM 2024 Neurologists Lack Awareness of Steroid Toxicity
Medscape Medical News, October 23, 2024
AANEM 2024 Remote Assessments a Win-Win for ALS Patients and Clinics?
Medscape Medical News, October 23, 2024
AANEM 2024 New Tool Aims to Stop ALS Diagnosis Delays
Medscape Medical News, October 22, 2024

AANEM 2024 Pediatric Myasthenia Gravis: Don’t Treat Kids Like Adults
Medscape Medical News, October 22, 2024
AANEM 2024 ALS Update: Drug Therapy Continues to Offer Little Benefit
Medscape Medical News, October 21, 2024
AANEM 2024 Cardiac Monitoring Is Crucial in Neuromuscular Disorder Care
Medscape Medical News, October 21, 2024
AANEM 2024 Myasthenia Gravis: What Role Does Heredity Play?
Medscape Medical News, October 18, 2024
AANEM 2024 Treatment Is in Sight for Charcot-Marie-Tooth Disease
Medscape Medical News, October 17, 2024
AANEM 2024 First-in-Class B-Cell Depleting Agent Promising for MG
Medscape Medical News, October 17, 2024
AANEM 2024 Sustained Control With New mAb for Myasthenia Gravis
Medscape Medical News, October 16, 2024

Disclaimer

Credit: iStock/Getty Images

Medscape Neurology©

Perspectives

Myasthenia Gravis Highlights From AANEM 2024
Pushpa Narayanaswami, MD

Popular News From AANEM 2023

First Treatment in 30 Years for Rare Disease Safe, Effective Subcutaneous efgartigimod PH20 SC is effective and tolerable for the treatment of CIDP, providing a convenient alternative to intravenous and other older treatments.
Medscape Medical News, Nov 06, 2023
Sustained Benefit for Newly Approved Myasthenia Gravis Drug Early responders to zilucoplan, the newly approved medication for myasthenia gravis have sustained benefit for up to 60 weeks, new analyses show.
Medscape Medical News, Nov 14, 2023
DMD Gene Therapy Safe, Effective at 4 Years Four years after a single dose of SRP-9001 gene therapy, four children with Duchenne muscular dystrophy show sustained stabilization of motor function that would otherwise show expected decline.
Medscape Medical News, Nov 06, 2023

Previous Coverage

AANEM 2023

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.